Anti-flavivirus compounds and methods of use

Patent metadata

Field	Value
Publication number	US-11096927-B2
Application number	US-201916721221-A
Country	US
Kind code	B2
Filing date	Dec 19, 2019
Priority date	Dec 19, 2018
Publication date	Aug 24, 2021
Grant date	Aug 24, 2021

Abstract

The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.

First claim

We claim:

1. A method for treating a Flavivirus infection in a human or non-human mammalian subject, said method comprising administering an effective amount of a compound to the subject having the Flavivirus infection, wherein the compound is colchicine, a prodrug of colchicine, a metabolite of colchicine, or a pharmaceutically acceptable salt of any of the foregoing, and wherein the Flavivirus infection is dengue virus infection or Zika virus infection.

2. The method of claim 1 , wherein the Flavivirus infection is dengue virus infection.

3. The method of claim 1 , wherein the compound is administered to the subject orally, nasally, rectally, parenterally, subcutaneously, intramuscularly, or intravascularly.

4. The method of claim 1 , further comprising administering an additional agent to the subject, for treating the Flavivirus infection, or a symptom thereof, in the same formulation as the compound, or in a separate formulation before, during, or after administration of the compound.

5. The method of claim 1 , wherein the compound is administered to the subject in a pharmaceutical composition that further comprises a pharmaceutically acceptable carrier or diluent.

6. The method of claim 1 , wherein the Flavivirus infection is Zika virus infection.

7. The method of claim 1 , wherein the compound is colchicine or a pharmaceutically acceptable salt thereof.

8. The method of claim 1 , wherein the compound is colchicine or a pharmaceutically acceptable salt thereof, and wherein the Flavivirus infection is dengue virus infection.

9. The method of claim 1 , wherein the compound is colchicine or a pharmaceutically acceptable salt thereof, and wherein the Flavivirus infection is Zika virus infection.

10. The method of claim 1 , wherein the subject is human, wherein the compound is colchicine or a pharmaceutically acceptable salt thereof, and wherein the Flavivirus infection is dengue virus infection.

11. The method of claim 1 , wherein the subject is human, wherein the compound is colchicine or a pharmaceutically acceptable salt thereof, and wherein the Flavivirus infection is Zika virus infection.

12. A method for inhibiting Flavivirus infection in human or non-human mammalian cells in vitro or in vivo, said method comprising contacting an effective amount of a compound to the human or non-human mammalian cell in vitro or in vivo after exposure of the cell to the Flavivirus, wherein the compound is colchicine, a prodrug of colchicine, a metabolite of colchicine, or a pharmaceutically acceptable salt of any of the foregoing, wherein the Flavivirus is dengue virus or Zika virus, and wherein the Flavivirus infection is dengue virus infection or Zika virus infection.

13. The method of claim 12 , wherein the Flavivirus is dengue virus, and wherein the Flavivirus infection is dengue virus infection.

14. The method of claim 12 , wherein the Flavivirus is Zika virus, and wherein the Flavivirus infection is Zika virus infection.

15. The method of claim 12 , wherein the compound is colchicine or a pharmaceutically acceptable salt thereof.

16. The method of claim 12 , wherein the compound is colchicine or a pharmaceutically acceptable salt thereof, wherein the Flavivirus is dengue virus, and wherein the Flavivirus infection is dengue virus infection.

17. The method of claim 12 , wherein the compound is colchicine or a pharmaceutically acceptable salt thereof, wherein the Flavivirus is Zika virus, and wherein the Flavivirus infection is Zika virus infection.

18. The method of claim 12 , wherein the cell is a human cell, wherein the compound is colchicine or a pharmaceutically acceptable salt thereof, wherein the Flavivirus is dengue virus, and wherein the Flavivirus infection is dengue virus infection.

19. The method of claim 12 , wherein the cell is a human cell, wherein the compound is colchicine or a pharmaceutically acceptable salt thereof, wherein the Flavivirus is Zika virus, and wherein the Flavivirus infection is Zika virus infection.

Assignees

• Univ Florida State Res Found
• Us Health
• Univ Pennsylvania

Inventors

• Tang Hengli
• Lee Emily M
• Zheng Wei
• Huang Ruili
• Xu Miao
• Huang Wenwei
• Shamim Khalida
• Ming Guoli
• Song Hongjun

Classifications

• A61K31/336

  having three-membered rings, e.g. oxirane, fumagillin · CPC title

• A61K31/506

  not condensed and containing further heterocyclic rings · CPC title

• A61K31/427

  not condensed and containing further heterocyclic rings · CPC title

• A61K31/165

  having aromatic rings, e.g. colchicine, atenolol, progabide · CPC title

• A61K31/4709

  Non-condensed quinolines and containing further heterocyclic rings · CPC title